These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10351127)

  • 1. Inhalation of estradiol for sustained systemic delivery.
    Wang J; Ben-Jebria A; Edwards DA
    J Aerosol Med; 1999; 12(1):27-36. PubMed ID: 10351127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation and physical characterization of large porous particles for inhalation.
    Vanbever R; Mintzes JD; Wang J; Nice J; Chen D; Batycky R; Langer R; Edwards DA
    Pharm Res; 1999 Nov; 16(11):1735-42. PubMed ID: 10571280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexamethasone palmitate large porous particles: A controlled release formulation for lung delivery of corticosteroids.
    N'Guessan A; Fattal E; Chapron D; Gueutin C; Koffi A; Tsapis N
    Eur J Pharm Sci; 2018 Feb; 113():185-192. PubMed ID: 28890202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients.
    Razavi Rohani SS; Abnous K; Tafaghodi M
    Int J Pharm; 2014 Apr; 465(1-2):464-78. PubMed ID: 24560646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method.
    You Y; Zhao M; Liu G; Tang X
    J Pharm Pharmacol; 2007 Jul; 59(7):927-34. PubMed ID: 17637186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
    Minne A; Boireau H; Horta MJ; Vanbever R
    Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary delivery of pyrazinamide-loaded large porous particles.
    Pham DD; Grégoire N; Couet W; Gueutin C; Fattal E; Tsapis N
    Eur J Pharm Biopharm; 2015 Aug; 94():241-50. PubMed ID: 26036447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct lung delivery of a dry powder formulation of DTPA with improved aerosolization properties: effect on lung and systemic decorporation of plutonium.
    Gervelas C; Serandour AL; Geiger S; Grillon G; Fritsch P; Taulelle C; Le Gall B; Benech H; Deverre JR; Fattal E; Tsapis N
    J Control Release; 2007 Mar; 118(1):78-86. PubMed ID: 17241685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes.
    Koushik K; Dhanda DS; Cheruvu NP; Kompella UB
    Pharm Res; 2004 Jul; 21(7):1119-26. PubMed ID: 15290850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerosolization properties, surface composition and physical state of spray-dried protein powders.
    Bosquillon C; Rouxhet PG; Ahimou F; Simon D; Culot C; Préat V; Vanbever R
    J Control Release; 2004 Oct; 99(3):357-67. PubMed ID: 15451594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large porous particles for pulmonary drug delivery.
    Edwards DA; Hanes J; Caponetti G; Hrkach J; Ben-Jebria A; Eskew ML; Mintzes J; Deaver D; Lotan N; Langer R
    Science; 1997 Jun; 276(5320):1868-71. PubMed ID: 9188534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of formulation components on the aerosolisation properties of spray-dried powders.
    Rabbani NR; Seville PC
    J Control Release; 2005 Dec; 110(1):130-40. PubMed ID: 16226334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic delivery of parathyroid hormone (1-34) using spray freeze-dried inhalable particles.
    Poursina N; Vatanara A; Rouini MR; Gilani K; Rouholamini Najafabadi A
    Pharm Dev Technol; 2017 Sep; 22(6):733-739. PubMed ID: 26708720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery.
    Cruz L; Fattal E; Tasso L; Freitas GC; Carregaro AB; Guterres SS; Pohlmann AR; Tsapis N
    J Control Release; 2011 Jun; 152(3):370-5. PubMed ID: 21396412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats.
    Carvalho SR; Watts AB; Peters JI; Liu S; Hengsawas S; Escotet-Espinoza MS; Williams RO
    Eur J Pharm Biopharm; 2014 Sep; 88(1):136-47. PubMed ID: 24859653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The preparation and application of pulmonary surfactant nanoparticles as absorption enhancers in insulin dry powder delivery.
    Zhang Y; Zhu J; Tang Y; Chen X; Yang Y
    Drug Dev Ind Pharm; 2009 Sep; 35(9):1059-65. PubMed ID: 19640250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excipient-free nanoporous microparticles of budesonide for pulmonary delivery.
    Nolan LM; Tajber L; McDonald BF; Barham AS; Corrigan OI; Healy AM
    Eur J Pharm Sci; 2009 Jul; 37(5):593-602. PubMed ID: 19463948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats.
    Codrons V; Vanderbist F; Verbeeck RK; Arras M; Lison D; Préat V; Vanbever R
    J Pharm Sci; 2003 May; 92(5):938-50. PubMed ID: 12712413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a new inhalable thymopentin formulation.
    Wang L; Zhang Y; Tang X
    Int J Pharm; 2009 Jun; 375(1-2):1-7. PubMed ID: 19443146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.